ICMR begins study on vaccine for people with poor immunity

Indian Council of Medical Research (ICMR), the country’s top health research body, has initiated a study to evaluate the effectiveness of Covid-19 vaccines in immunocompromised people. Experts say the results are likely in the next six months. The study includes some people with kidney related problems and some on dialysis, among others, they said.

“This way, we will get to know the magnitude of the problem,” said J Muliyil, a member of National Technical Advisory Group on Immunisation (NTAGI).

The study will see how immunocompromised people are responding to existing Covid-19 vaccines, including Covishield and Covaxin. It will also evaluate the effect of a booster shot on these people when it is the same as the one given earlier and also when it’s a different vaccine.

“The study will evaluate how they are responding to vaccines and how giving them a booster dose of the same vaccine and a different vaccine will work,” said Muliyil.

Prime Minister Narendra Modi on Saturday announced that booster shots should be administered to health and frontline workers and those above 60 with comorbidities from January 10. He also said vaccinations will begin for children between 15 and 18 years from January 3.

While the announcement comes as a relief to many, experts say data is needed.

“We have to see whether people who are immunocompromised due to associated disease conditions cannot mount enough immune response. Studies are needed to understand the same and data is generated to see the response of the available vaccines in immunocompromised people,” said an expert at ICMR.

  • Related Posts

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    Meerut: A four-year-old boy’s condition allegedly worsened after he was administered an anti-rabies injection at Sambhal district hospital following a snakebite. A pharmacist at the hospital has been removed from…

    Lupin gets tentative US FDA nod for apixaban oral suspension for patients who cannot swallow tablets

    Once final approval comes through, the liquid anticoagulant will be made at Lupin’s plant in Somerset, New Jersey, the company said. Mumbai: Lupin has received tentative approval from the US…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

    Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

    Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

    Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

    Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

    Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

    Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

    Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

    Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore

    Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore